Join to View Full Profile
915 N Grand BlvdVa Medical Center, Renal Section, Room 533St. Louis, MO 63106
Phone+1 314-289-6485
Dr. Al-Aly is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
SSM Health/Saint Louis University School of MedicineFellowship, Nephrology, 2003 - 2006- SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 2000 - 2003
American University of Beirut Faculty of MedicineClass of 1999
Certifications & Licensure
MO State Medical License 2003 - 2027
CA State Medical License 2010 - 2020
Publications & Presentations
PubMed
- GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy.Taeyoung Choi, Ziyad Al-Aly, Yan Xie
JAMA Network Open. 2026-04-01 - Clinical practice guideline for long COVID prevention and treatment.Bin Cao, Joan B Soriano, Quanyi Wang, Ziyad Al-Aly, Xiaoying Gu
The European Respiratory Journal. 2026-03-19 - Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.Miao Cai, Taeyoung Choi, Yan Xie, Ziyad Al-Aly
BMJ. 2026-03-04
Journal Articles
- Air Pollution and Kidney DiseaseZiyad Al-Aly, MD, American Society of Nephrology
- Analysis of the Global Burden of Disease Study Highlights the Global, Regional, and National Trends of Chronic Kidney Disease Epidemiology from 1990 to 2016Geetha Maddukuri, Ziyad Al-Aly, Kidney International
- Risk of Death Among Users of Proton Pump Inhibitors: A Longitudinal Observational Cohort Study of United States VeteransYan Yan, Ziyad Al-Aly, Tingting Li, Emergency Medicine Journal
Authored Content
- Risk of Death Among Users of Proton Pump Inhibitors: A Longitudinal Observational Cohort Study of United States VeteransJuly 2017
Press Mentions
Stopping GLP-1s Linked to 22% Rise in Heart Attack: 5 Study NotesMarch 20th, 2026- Stopping GLP-1 Drugs Can Quickly Erase Cardiovascular BenefitsMarch 18th, 2026
- GLP-1s Have Transformed Weight Loss and Diabetes. Is Addiction Next?March 10th, 2026
Grant Support
- Long-term Cardiometabolic Disease in COVID-19ST. LOUIS VA MEDICAL CENTER2025–2029
- Comparative Effectiveness and Safety of Newer and Older Antihyperglycemic MedicationsST. LOUIS VA MEDICAL CENTER2021–2026
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
